Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
The purpose of this study is to perform a randomized Phase II evaluation of
Carboplatin/Paclitaxel with or without Trastuzumab (Herceptin) in patients with HER2/neu+
advanced stage/recurrent disease with an emphasis on determining the progression free
survival in USPC patients and assessing immunologic markers predictive of trastuzumab
response.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival differences between Arm A versus Arm B.
Progression free survival differences between Arm A versus Arm B.
4 years
Yes
Alessandro D Santin, M.D.
Principal Investigator
Yale University
United States: Institutional Review Board
1012007786
NCT01367002
June 2011
July 2015
Name | Location |
---|---|
St. Joseph's Hospital and Medical Center | Phoenix, Arizona 85001-2071 |
University of Connecticut Health Center | Farmington, Connecticut 06360-7106 |
Montefiore Medical Center | Bronx, New York 10467-2490 |
Greater Baltimore Medical Center | Baltimore, Maryland 21204 |
University of Virginia | Charlottesville, Virginia 22908 |
University of North Carolina | Chapel Hill, North Carolina 27599 |
The Ohio State University | Columbus, Ohio 43210 |
Holy Cross Hospital | Silver Spring, Maryland 20910 |
Jersey Shore University Medical Center | Neptune, New Jersey 07754 |
University of California at Los Angeles | Los Angeles, California 90095 |
Duke University School of Medicine | Durham, North Carolina 27710 |
Smilow Cancer Hospital at Yale New Haven | New Haven, Connecticut 06510 |
John Muir Clinical Research Center | Concord, California 94520 |